Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs.

Initiation of rifaximin after an OHE hospitalization was associated with reduced OHE hospitalizations both in the 30-days following and annually. Further, reduced medical costs offset increased pharmacy costs, and no annual cost differences were observed between cohorts.